SciELO - Scientific Electronic Library Online

 
vol.27 issue2Impact of epidermal growth factor on the treatment of diabetic foot ulcersImplementation of an integral health program for diabetic foot ulcer patients by using Heberprot-P at the primary health attention level in the municipality of Playa, in Havana, Cuba author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Biotecnología Aplicada

On-line version ISSN 1027-2852

Abstract

GIL, Miriela R et al. Experiences in the nationwide program for the integral care of the patient with diabetic foot ulcer using Heberprot-P. Biotecnol Apl [online]. 2010, vol.27, n.2, pp.147-150. ISSN 1027-2852.

Experiences in the nationwide program for the integral care of the patient with diabetic foot ulcer using Heberprot-P. The Cuban product Heberprot-P is indicated for the treatment of complex diabetic foot ulcers (DFU). After its registration in 2006, the product was included into the Cuban List of Medicines and a nationwide program for the integral care of the DFU patient began. To date Heberprot-P is available in more than 85 Cuban health institutions and more than 3 800 diabetic patients with ulcers in their feet have received the benefits of this unique product. An integral program has been established for the attention of the patient with DFU, including the advanced technology of Heberprot-P. This program relies on the closely linked and coordinated interaction between the primary and secondary levels of health, in which prevention and therapy merge each other. The Ministry of Public Health of Cuba has established impact indicators in order to control and assess the performance of the program.

Keywords : Heberprot-P; Diabetic foot ulcer; Primary Health Care.

        · abstract in Spanish     · text in English     · English ( pdf )